Seqirus announced this week that the US Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older.
AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), are available in the US for the 2016-2017 influenza season.
AFLURIA QUADRIVALENT is the second quadrivalent influenza vaccine that Seqirus is offering this season after the FDA approved FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) in May. AFLURIA QUADRIVALENT comes in single-dose, preservative-free pre-filled syringes while AFLURIA, indicated for persons 5 years of age and older, is available in prefilled syringes and multi-dose vials to provide choice and convenience to patients and caregivers who administer it.
“As a new quadrivalent seasonal influenza vaccine, AFLURIA QUADRIVALENT will provide healthcare providers and their patients with an important option to further broaden their influenza vaccine offerings,” said Gordon Naylor, President of Seqirus.
“Seqirus is proud to be a leader in the prevention and control of seasonal influenza by offering a range of clinically proven vaccines to help protect people against the debilitating effects of the disease. AFLURIA QUADRIVALENT is the latest example of how Seqirus is delivering on its promise to help improve public health around the world.” Seqirus has earlier announced the availability of Fluad™ (Influenza Vaccine, Adjuvanted), Fluvirin® (Influenza Virus Vaccine) and Flucelvax Quadrivalent for the 2016-2017 influenza season.